Clinical Trial Update: Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of Egalet-002 for moderate-to-severe chronic low back pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain

Drugs mentioned

• Egalet-002

Snippet

Sponsor: Egalet Ltd | Conditions: Moderate-to-severe Chronic Low Back Pain | Phase 3 | Status: COMPLETED